Citigroup
MCRB icon

Citigroup’s Seres Therapeutics MCRB Stock Holding History

Citigroup’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,621
Closed -$50.4K – 6293
2025
Q3 		$50.4K Buy
2,621
+2,612
+29,022% +$41.7K ﹤0.01% 4498
2025
Q2 		$100 Sell
9
-2
-18% -$18 ﹤0.01% 5514
2025
Q1 		$151 Sell
11
-173
-94% -$2.71K ﹤0.01% 5425
2024
Q4 		$3.06K Sell
184
-10,728
-98% -$174K ﹤0.01% 5518
2024
Q3 		$206K Buy
10,912
+10,240
+1,524% +$208K ﹤0.01% 4326
2024
Q2 		$9.73K Sell
672
-222
-25% -$3.7K ﹤0.01% 5147
2024
Q1 		$13.8K Sell
894
-3,522
-80% -$75.9K ﹤0.01% 5127
2023
Q4 		$124K Sell
4,416
-19,825
-82% -$521K ﹤0.01% 4111
2023
Q3 		$1.15M Buy
24,241
+11,486
+90% +$877K ﹤0.01% 2393
2023
Q2 		$1.22M Buy
12,755
+2,994
+31% +$326K ﹤0.01% 2680
2023
Q1 		$1.11M Buy
9,761
+2,627
+37% +$284K ﹤0.01% 2461
2022
Q4 		$799K Sell
7,134
-2,404
-25% -$322K ﹤0.01% 2825
2022
Q3 		$1.23M Buy
9,538
+9,070
+1,938% +$929K ﹤0.01% 2558
2022
Q2 		$32K Sell
468
-2,148
-82% -$185K ﹤0.01% 4760
2022
Q1 		$373K Sell
2,616
-10,707
-80% -$1.65M ﹤0.01% 3699
2021
Q4 		$2.22M Sell
13,323
-2,823
-17% -$449K ﹤0.01% 2545
2021
Q3 		$2.25M Buy
16,146
+6,003
+59% +$1.17M ﹤0.01% 2453
2021
Q2 		$4.84M Buy
10,143
+119
+1% +$50.2K ﹤0.01% 1919
2021
Q1 		$4.13M Buy
10,024
+9,212
+1,134% +$4.24M ﹤0.01% 1918
2020
Q4 		$398K Buy
812
+305
+60% +$179K ﹤0.01% 4409
2020
Q3 		$287K Sell
507
-2,092
-80% -$696K ﹤0.01% 4320
2020
Q2 		$247K Buy
2,599
+1,809
+229% +$159K ﹤0.01% 4860
2020
Q1 		$56K Buy
790
+103
+15% +$6.91K ﹤0.01% 5879
2019
Q4 		$47K Buy
687
+451
+191% +$33.4K ﹤0.01% 6352
2019
Q3 		$19K Sell
236
-162
-41% -$10.7K ﹤0.01% 6765
2019
Q2 		$25K Buy
398
+41
+11% +$3.89K ﹤0.01% 6968
2019
Q1 		$49K Buy
357
+74
+26% +$9.02K ﹤0.01% 6354
2018
Q4 		$26K Sell
283
-3
-1% -$420 ﹤0.01% 6739
2018
Q3 		$43K Buy
286
+236
+472% +$38.2K ﹤0.01% 6643
2018
Q2 		$9K Sell
50
-5
-9% -$817 ﹤0.01% 7222
2018
Q1 		$8K Sell
55
-4
-7% -$767 ﹤0.01% 7114
2017
Q4 		$12K Buy
59
+2
+4% +$411 ﹤0.01% 6960
2017
Q3 		$18K Sell
57
-3
-5% -$820 ﹤0.01% 6476
2017
Q2 		$14K Buy
60
+10
+20% +$2.05K ﹤0.01% 6414
2017
Q1 		$11K Sell
50
-330
-87% -$67K ﹤0.01% 6526
2016
Q4 		$75K Sell
380
-277
-42% -$60.4K ﹤0.01% 5942
2016
Q3 		$162K Buy
657
+256
+64% +$89.8K ﹤0.01% 4826
2016
Q2 		$233K Sell
401
-222
-36% -$130K ﹤0.01% 4350
2016
Q1 		$331K Buy
623
+222
+55% +$116K ﹤0.01% 4591
2015
Q4 		$281K Buy
401
+215
+116% +$141K ﹤0.01% 4423
2015
Q3 		$110K Buy
+186
New +$152K ﹤0.01% 4911

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Citigroup's MCRB Position: Q4 2025 in Review

Citigroup sold out of Seres Therapeutics (MCRB) in Q4 2025, closing a stake of 2,621 shares — an estimated $50.4K sold.

Citigroup first reported a position in MCRB in Q3 2015 and held it in 41 quarters. The position peaked at $4.84M in Q2 2021. 36 funds tracked by Wall St. Rank hold MCRB as of Q4 2025.

  • Citigroup reported no remaining Seres Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 2,621 Seres Therapeutics shares in Q4 2025, an estimated $50.4K.
  • Citigroup first reported a position in Seres Therapeutics in Q3 2015 and held it in 41 quarters.
  • Citigroup's Seres Therapeutics position peaked at $4.84M in Q2 2021.
  • 36 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.